
Anita M King
Examiner (ID: 15142)
Most Active Art Unit | 3632 |
Art Unit(s) | 3505, 2899, 3632 |
Total Applications | 2681 |
Issued Applications | 2122 |
Pending Applications | 127 |
Abandoned Applications | 408 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13705341
[patent_doc_number] => 20170363625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-21
[patent_title] => QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
[patent_app_type] => utility
[patent_app_number] => 15/610321
[patent_app_country] => US
[patent_app_date] => 2017-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15610321
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/610321 | QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS | May 30, 2017 | Abandoned |
Array
(
[id] => 16976165
[patent_doc_number] => 20210220402
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENEIC T CELLS
[patent_app_type] => utility
[patent_app_number] => 16/303680
[patent_app_country] => US
[patent_app_date] => 2017-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303680
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/303680 | METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENEIC T CELLS | May 24, 2017 | Pending |
Array
(
[id] => 14464747
[patent_doc_number] => 20190184013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-20
[patent_title] => COMPOSITIONS FOR SELECTIVE HUMORAL RESPONSES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/302457
[patent_app_country] => US
[patent_app_date] => 2017-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302457
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/302457 | COMPOSITIONS FOR SELECTIVE HUMORAL RESPONSES AND METHODS OF USE THEREOF | May 22, 2017 | Abandoned |
Array
(
[id] => 12117312
[patent_doc_number] => 20180000899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'MODIFYING MACROPHAGE PHENOTYPE FOR TREATMENT OF DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/596945
[patent_app_country] => US
[patent_app_date] => 2017-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11690
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596945
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/596945 | MODIFYING MACROPHAGE PHENOTYPE FOR TREATMENT OF DISEASE | May 15, 2017 | Abandoned |
Array
(
[id] => 12680887
[patent_doc_number] => 20180118795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-03
[patent_title] => DENDRITIC CELL INHIBITORY PROTEINS FROM TICKS
[patent_app_type] => utility
[patent_app_number] => 15/595387
[patent_app_country] => US
[patent_app_date] => 2017-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595387
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/595387 | DENDRITIC CELL INHIBITORY PROTEINS FROM TICKS | May 14, 2017 | Abandoned |
Array
(
[id] => 15296033
[patent_doc_number] => 20190391152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS
[patent_app_type] => utility
[patent_app_number] => 16/301805
[patent_app_country] => US
[patent_app_date] => 2017-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301805
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/301805 | MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS | May 14, 2017 | Abandoned |
Array
(
[id] => 12217560
[patent_doc_number] => 20180055919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-03-01
[patent_title] => 'ANTIGEN SPECIFIC TREGS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS'
[patent_app_type] => utility
[patent_app_number] => 15/499805
[patent_app_country] => US
[patent_app_date] => 2017-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 23334
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15499805
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/499805 | Antigen specific Tregs and related compositions, methods and systems | Apr 26, 2017 | Issued |
Array
(
[id] => 16956046
[patent_doc_number] => 11059888
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Regulatory T cell activator and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/095024
[patent_app_country] => US
[patent_app_date] => 2017-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 63
[patent_no_of_words] => 15644
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095024
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/095024 | Regulatory T cell activator and use thereof | Apr 18, 2017 | Issued |
Array
(
[id] => 12001868
[patent_doc_number] => 20170306024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/489254
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 129
[patent_figures_cnt] => 129
[patent_no_of_words] => 81532
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489254
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489254 | Anti-human vista antibodies and use thereof | Apr 16, 2017 | Issued |
Array
(
[id] => 16985500
[patent_doc_number] => 11072656
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-27
[patent_title] => Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/489666
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 31420
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489666
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489666 | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof | Apr 16, 2017 | Issued |
Array
(
[id] => 12001866
[patent_doc_number] => 20170306021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/489192
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 128
[patent_figures_cnt] => 128
[patent_no_of_words] => 81643
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489192
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489192 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Apr 16, 2017 | Abandoned |
Array
(
[id] => 12001865
[patent_doc_number] => 20170306019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/489164
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 130
[patent_figures_cnt] => 130
[patent_no_of_words] => 81712
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489164
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489164 | Anti-human vista antibodies and use thereof | Apr 16, 2017 | Issued |
Array
(
[id] => 12001867
[patent_doc_number] => 20170306022
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/489209
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 130
[patent_figures_cnt] => 130
[patent_no_of_words] => 81688
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489209
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489209 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Apr 16, 2017 | Pending |
Array
(
[id] => 18246830
[patent_doc_number] => 11603403
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-14
[patent_title] => Anti-human vista antibodies and use thereof
[patent_app_type] => utility
[patent_app_number] => 15/489245
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 128
[patent_figures_cnt] => 155
[patent_no_of_words] => 75928
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489245
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489245 | Anti-human vista antibodies and use thereof | Apr 16, 2017 | Issued |
Array
(
[id] => 12001864
[patent_doc_number] => 20170306020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/489189
[patent_app_country] => US
[patent_app_date] => 2017-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 129
[patent_figures_cnt] => 129
[patent_no_of_words] => 80631
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489189
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/489189 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Apr 16, 2017 | Abandoned |
Array
(
[id] => 17586545
[patent_doc_number] => 11324787
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Analytical methods and arrays for use in the same
[patent_app_type] => utility
[patent_app_number] => 16/084788
[patent_app_country] => US
[patent_app_date] => 2017-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 13
[patent_no_of_words] => 25419
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 325
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084788
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/084788 | Analytical methods and arrays for use in the same | Mar 21, 2017 | Issued |
Array
(
[id] => 11820633
[patent_doc_number] => 20170209570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-27
[patent_title] => 'Carbon Nanotube Compositions and Methods of Use Thereof'
[patent_app_type] => utility
[patent_app_number] => 15/462320
[patent_app_country] => US
[patent_app_date] => 2017-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 28314
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462320
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/462320 | Carbon nanotube compositions and methods of use thereof | Mar 16, 2017 | Issued |
Array
(
[id] => 11954747
[patent_doc_number] => 20170258898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-14
[patent_title] => 'VERSIKINE FOR INDUCING AND POTENTIATING AN IMMUNE RESPONSE'
[patent_app_type] => utility
[patent_app_number] => 15/454496
[patent_app_country] => US
[patent_app_date] => 2017-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 23784
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15454496
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/454496 | Versikine for inducing and potentiating an immune response | Mar 8, 2017 | Issued |
Array
(
[id] => 11937737
[patent_doc_number] => 20170241887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-24
[patent_title] => 'Isolating Cells Expressing Secreted Proteins'
[patent_app_type] => utility
[patent_app_number] => 15/443290
[patent_app_country] => US
[patent_app_date] => 2017-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23910
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15443290
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/443290 | Isolating Cells Expressing Secreted Proteins | Feb 26, 2017 | Abandoned |
Array
(
[id] => 13970489
[patent_doc_number] => 10214587
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-26
[patent_title] => Depletion of plasmacytoid dendritic cells
[patent_app_type] => utility
[patent_app_number] => 15/442147
[patent_app_country] => US
[patent_app_date] => 2017-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 23
[patent_no_of_words] => 14199
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15442147
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/442147 | Depletion of plasmacytoid dendritic cells | Feb 23, 2017 | Issued |